Earnings summaries and quarterly performance for Jefferies Financial Group.
Executive leadership at Jefferies Financial Group.
Board of directors at Jefferies Financial Group.
JK
Jacob Katz
Detailed
Director
LA
Linda Adamany
Detailed
Lead Independent Director
MG
MaryAnne Gilmartin
Detailed
Director
ME
Matrice Ellis Kirk
Detailed
Director
MW
Melissa Weiler
Detailed
Director
MO
Michael O'Kane
Detailed
Director
RB
Robert Beyer
Detailed
Director
TJ
Thomas Jones
Detailed
Director
TN
Toru Nakashima
Detailed
Director
Research analysts covering Jefferies Financial Group.
Recent press releases and 8-K filings for JEF.
Jefferies Financial Group Inc. announces pricing of $1.5 billion senior notes offering
JEF
Debt Issuance
- Jefferies Financial Group Inc. (JEF) announced the pricing of its public offering of $1.5 billion aggregate principal amount of 5.500% Senior Notes due 2036 on January 13, 2026.
- The notes have an effective yield of 5.605% and are scheduled to mature on February 15, 2036.
- The offering is expected to settle on January 16, 2026, with the net proceeds intended for general corporate purposes.
1 day ago
Jefferies Financial Group Reports Q4 and Full Year 2025 Results, Expands SMBC Alliance, and Announces New Investment
JEF
Earnings
M&A
New Projects/Investments
- Jefferies Financial Group reported $7.3 billion in Net Revenues and $631 million in Net Earnings for the full year 2025. Investment Banking net revenues increased 10% to $3.8 billion in 2025, including a record $1.2 billion in the fourth quarter.
- The company significantly expanded its Global Strategic Alliance with Sumitomo Mitsui Banking Corporation (SMBC), which plans to increase its equity ownership in Jefferies to up to 20% and provide $2.5 billion in new credit facilities. A joint venture in Japan for equities and ECM businesses is set to begin in January 2027.
- Jefferies agreed to acquire a 50% interest in Hildene Holding Company, LLC, a credit-focused asset manager with over $18 billion of assets under management, which is also acquiring SILAC Inc..
7 days ago
Jefferies Financial Group Inc. Announces Fourth Quarter and Full Year 2025 Financial Results
JEF
Earnings
Dividends
Share Buyback
- Jefferies Financial Group Inc. reported total net revenues of $2.07 billion for Q4 2025.
- For Q4 2025, net earnings attributable to common shareholders were $191 million, resulting in diluted earnings per common share from continuing operations of $0.87.
- Adjusted net earnings attributable to common shareholders for Q4 2025 were $213 million, or $0.96 per adjusted diluted share.
- Investment Banking net revenues for Q4 2025 increased 20% to $1.19 billion, and Capital Markets net revenues increased 6% to $692 million compared to the prior year quarter.
- The Board of Directors declared a quarterly cash dividend of $0.40 per common share, payable on February 27, 2026. The company also repurchased 0.7 million shares of common stock for $59 million in fiscal year 2025.
7 days ago
Jefferies Announces Fourth Quarter 2025 Financial Results
JEF
Earnings
Dividends
Revenue Acceleration/Inflection
- Jefferies Financial Group reported net earnings attributable to common shareholders of $190.89 million and diluted earnings per common share from continuing operations of $0.87 for the fourth quarter of 2025.
- Total net revenues for Q4 2025 were $2.07 billion, with Investment Banking net revenues increasing 20% to $1.19 billion and Capital Markets net revenues increasing 6% to $692 million compared to the prior year quarter.
- The company's Board of Directors declared a quarterly cash dividend of $0.40 per common share, payable on February 27, 2026, to record holders on February 17, 2026.
- Adjusted diluted earnings per common share from continuing operations for Q4 2025 were $0.96, with an adjusted return on adjusted tangible shareholders' equity of 12.9%.
7 days ago
FactSet Reports First Quarter Fiscal 2026 Results
JEF
Earnings
Share Buyback
Guidance Update
- FactSet reported Q1 fiscal 2026 GAAP revenues of $607.6 million, an increase of 6.9% from the prior year, with organic revenues growing 6.0% to $600.0 million.
- GAAP diluted EPS for Q1 fiscal 2026 was $4.06, up 4.4%, and adjusted diluted EPS was $4.51, up 3.2% year over year.
- Organic Annual Subscription Value (ASV) reached $2,389.6 million as of November 30, 2025, marking a 5.9% year-over-year increase.
- FactSet's Board of Directors approved an increase to the existing share repurchase authorization from $400 million to $1 billion, with an additional $600 million in authority approved on December 16, 2025.
- The company reaffirmed its fiscal 2026 outlook, projecting GAAP revenues between $2,423 million and $2,448 million and adjusted diluted EPS in the range of $16.90 to $17.60.
Dec 18, 2025, 12:00 PM
Howard Hughes Holdings to Acquire Vantage Group Holdings for $2.1 Billion
JEF
M&A
New Projects/Investments
Convertible Preferred Issuance
- Howard Hughes Holdings Inc. (HHH) has entered into a definitive agreement to acquire Vantage Group Holdings Ltd., a privately held specialty insurance and reinsurance company, for approximately $2.1 billion.
- The transaction is expected to close in the second quarter of 2026, subject to customary regulatory approvals, and will anchor HHH's transformation into a diversified holding company.
- The acquisition will be financed through HHH’s cash on hand and up to $1 billion of non-interest-bearing, non-voting preferred stock issued by HHH to Pershing Square Holdings, Ltd..
- Pershing Square will manage Vantage’s investment portfolio on a fee-free basis, aiming to enhance investment returns and align with policyholders and shareholders.
Dec 18, 2025, 11:00 AM
Jefferies to Acquire 50% Stake in Hildene Holding
JEF
M&A
New Projects/Investments
Guidance Update
- Jefferies Financial Group is acquiring a 50% interest in Hildene Holding Company, the parent of credit-focused asset manager Hildene Capital Management, for $340 million in cash.
- The acquisition, expected to close in Q3 2026, is anticipated to be immediately accretive and a consistent contributor to Jefferies' net earnings, with a projected $75 million pretax gain after closing.
- The $340 million cash investment will be offset by an anticipated over $500 million reduction in Jefferies’ investments in its Leucadia Asset Management division during 2026.
- This strategic move aligns with Jefferies' goal to expand credit origination and asset management, and coincides with Hildene's agreement to acquire SILAC, a fixed-indexed annuity provider.
Dec 8, 2025, 11:53 AM
Jefferies to Acquire 50% Interest in Hildene Holding Company
JEF
M&A
New Projects/Investments
- Jefferies Financial Group Inc. is acquiring a 50% interest in Hildene Holding Company, a credit-focused asset manager with over $18 billion of assets under management.
- The acquisition involves $340 million in cash from Jefferies, an exchange of its existing revenue share in Hildene, and a portion of its interest in a Hildene-managed private fund.
- This $340 million cash investment will be effectively funded by an anticipated over $500 million reduction in Jefferies' Leucadia Asset Management division's investments during 2026.
- The transaction is expected to close in the third quarter of 2026 and is anticipated to be immediately accretive to Jefferies' net earnings, with an expected $75 million pretax gain from the fair market value markup of its pre-transaction interest.
- Concurrently, Hildene will acquire SILAC, Inc., an annuity provider with approximately $10 billion of total admitted assets as of September 30, 2025, for $550 million in cash upon regulatory approval.
Dec 8, 2025, 11:52 AM
Crescent Biopharma Announces Strategic Partnership and $185 Million Private Placement
JEF
New Projects/Investments
Convertible Preferred Issuance
- Crescent Biopharma announced an exclusive partnership with Kelun-Biotech to develop and commercialize oncology therapeutics, granting Kelun-Biotech rights to CR-001 in Greater China and Crescent rights to SKB105 (CR-003) in the United States, Europe, and other markets outside Greater China.
- The company's pipeline programs, CR-001, CR-002, and CR-003 (SKB105), are on track to enter the clinic in 2026, with initial Phase 1/2 trials for CR-001 and CR-003 (SKB105) expected to begin in Q1 2026 and proof-of-concept data anticipated in Q1 2027.
- Crescent Biopharma secured a $185 million private placement, expected to close around December 8, 2025, which is projected to provide a cash runway into 2028.
Dec 4, 2025, 11:35 AM
SEC Investigates Jefferies Over First Brands Exposure Disclosures
JEF
Legal Proceedings
- The U.S. Securities and Exchange Commission (SEC) is investigating Jefferies Financial Group regarding its disclosures to investors concerning its exposure to First Brands Group, a bankrupt auto parts supplier.
- The probe focuses on Jefferies' Point Bonita Capital fund, which held approximately $715 million in receivables tied to First Brands, and whether this exposure was adequately disclosed.
- The investigation also examines potential internal control weaknesses, conflicts of interest, and undisclosed fees Jefferies may have received through a side letter with First Brands.
- Jefferies' CEO stated the bank believes it was "defrauded" by First Brands, but emphasized that the collapse did not seriously harm Jefferies' core business.
Nov 27, 2025, 3:10 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more